SMALL LYMPHOCYTIC LYMPHOMA

This study tests whether a two-shot pneumonia vaccine series (PCV20 and PPSV23) can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 participants with CLL, either untreated or on a specific drug, will re…

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This early-phase study tests azer-cel, a pre-made (allogeneic) CAR T cell therapy, in adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related blood cancers. The goal is to check safety and see if these donor-derived cells can shri…

This study tests two drug combinations—acalabrutinib plus venetoclax or obinutuzumab—in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if these combinations can shrink tumors and reduce cancer cells to undetectable level…

This study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study tests a combination of three drugs (venetoclax, obinutuzumab, and possibly acalabrutinib) in people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or not responded to prior treatment. The goal is to see if the treatment can eliminate…

This study compares starting treatment right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants receive a combination of two drugs: venetoclax (which blocks a protein that he…

This study is testing a new drug called AZD0486, either alone or with other cancer drugs, in people with certain types of blood cancers like leukemia and lymphoma. The goal is to see if the drug is safe and works against the cancer. About 408 adults will take part in this early-p…

This study tests whether adding obinutuzumab to acalabrutinib works better than acalabrutinib alone for people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are at high risk of their disease getting worse. About 120 adults will be ran…

This study compares an experimental drug, BGB-16673, to an approved drug, pirtobrutinib, in about 500 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or didn't respond after prior treatment with a BTK inhibitor. The main go…

This study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of targeted therapy will get epcor…

This study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor, can clear tiny amounts of leftover leukemia cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who are already on or have recently finis…

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study tests two approaches for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma: a combination of ibrutinib and venetoclax, or ibrutinib alone. The key idea is to adjust the ibrutinib dose—either by starting lower or changing it based on…

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) in people who have not yet been treated. The goal is to see if patients can stop treatment for a while without the cancer coming back. About 60 adults…

This study tests a faster way to increase the dose of sonrotoclax, a drug that blocks a protein helping cancer cells survive. It is given after initial treatment with zanubrutinib or rituximab. The trial includes 30 adults with chronic lymphocytic leukemia, small lymphocytic lymp…

This study tests whether combining two targeted drugs, pirtobrutinib and venetoclax, can kill more cancer cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease progressed despite standard BTK inhibitor therapy. About 30 adults w…

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study is for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. It tests a one-year treatment with two drugs, pirtobrutinib and obinutuzumab, to see how well they control the disease. About 60 participants will receive the therapy for 12 cycles…

This study looks at two different schedules of a drug combination (venetoclax and acalabrutinib) for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 62 participants will either take venetoclax continuously or only for part of the time, to s…

This study tests a treatment called CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified in a lab to recognize and attack cancer cells, and then returned to the b…

This study tests a new drug called BGB-16673 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer returned or stopped responding after treatment with a BTK inhibitor. About 150 participants will receive either BGB-16673 or one of two …

This large Phase 3 study compares a new drug, nemtabrutinib, with two standard treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet received any therapy. The goal is to see if nemtabrutinib works as we…

This study tests whether adding a drug called epcoritamab to the usual two-drug treatment (venetoclax and obinutuzumab) can make cancer disappear more completely in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 33 adults will …

This study tests whether a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) can help people with Richter transformation, a rare and aggressive lymphoma that develops from chronic lymphocytic leukemia (CLL). The drugs work by blocking cancer growth signals, t…

This study compares a newer targeted drug, pirtobrutinib, to an older one, ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 662 participants will be enrolled, some who have had prior treatment and some who have not. The goal …

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it shrinks tumors and how safe it is. The goal is to …

This study tests a new drug, sonrotoclax, combined with antibody therapy for adults with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630 participants will be randomly assigned to receive either the new combination or a standard trea…

This study tests three different doses of an experimental drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond to a previous type of targeted therapy (a BTK inhibitor). The goal is…

This study is for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). It compares staying on the BTKi pill alone versus adding a second pill, venetoclax, for one year and then stopping both. The g…

This study tests whether giving yearly pneumococcal vaccines to people with chronic lymphocytic leukemia (CLL) offers better protection than the current standard of revaccination every 5 years. About 80 adults with untreated CLL will receive either an initial vaccine followed by …

This study looks at the costs and quality of life for people with high-risk chronic lymphocytic leukemia (CLL) who start treatment early versus waiting. Researchers will track medical visits, tests, and hospital stays over 10 years. The goal is to find out which approach gives th…

This study follows up to 1,000 adults with certain blood cancers (CLL, SLL, LPL, or WM) to learn how these diseases change over time. Participants get regular check-ups, blood tests, and optional scans or biopsies, but no treatment is given. The goal is to better understand the d…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…